Research article · 31 Dec 2020
Conference abstractPublished 8 Oct 2015
Intestinal endocrine cells as biomarkers for the diagnosis of irritable bowel syndrome
Stord Hospital, Norway
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
The diagnosis of Irritable Bowel Syndrome (IBS) in clinical practice is a diagnosis of exclusion, whereby diagnostic tests and invasive investigations are conducted to exclude other gastrointestinal diseases. Attempts have been made to achieve a positive diagnosis based on symptoms assessment such as the Rome III criteria. However, symptom-based diagnosis is not widely used in everyday clinical practice. Searches for biomarkers for the diagnosis of IBS that reflect pathological states have not yielded any useful candidates. The duodenum contains the largest number of endocrine cells in the gastrointestinal tract, followed by the rectum. The densities of four of the five duodenal endocrine cell types have been found to be reduced in patients with sporadic (non-specific) IBS. Chromogranin A (CgA) is a common marker for gastrointestinal endocrine cells. It has been thought that the cell density of CgA the duodenal endocrine cells, can be used as a biomarker for the diagnosis of IBS. Receiver Operator Characteristic (ROC) revealed areas under the ROC curve (ROCAUC) values of 0.97, and positive likelihood (+LH) and negative LR (-LH) of 18.5 and 0.14, respectively. This biomarker is simple, inexpensive, and easy to perform, and does not require sophisticated equipment or considerable experience. The density of PYY cells is reduced in the rectum of sporadic IBS patients, whereas that of somatostatin is increased. As biomarkers for the diagnosis of IBS, rectal PYY has a ROCAUC values of 0.96 and +LH and âÂ?Â?LH 7.56 and 0.18, respectively. The corresponding values for somatostatin are 0.93, 7.20, and 0.23. These biomarkers erform well in differentiating IBS from health and are better than Rome III criteria, which has +LH and âÂ?Â?LH of 3.53 and 0.39, respectively. Moreover, these biomarkers reflect an anatomical lesions occurring in the gastrointestinal tract of IBS patients, namely gastrointestinal endocrine cells.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 15 Apr 2014
Duodenal chromogranin: A cell density as a biomarker for the diagnosis of irritable bowel syndrome
Commentary · 30 Oct 2022
Food reactions mediated by the immune system in irritable bowel syndrome
Research article · 27 May 2022
Pattern Of Irritable Bowel Syndrome And Its Symptoms Characteristics A Study From Tertiary Care Hospital In North India
Research article · 1 Jan 2022
Network Pharmacology and Molecular Docking Analysis on Molecular Mechanism and Key Targets of Xiaoyao Powder in the Treatment of Irritable Bowel Syndrome
More from this journal
The newest in Journal of Pharmaceutical Care & Health Systems.
Review article · 9 Jun 2025
Blood Fluid: The Unseen Currents That Bind Life and Death Together
Research article · 8 Jun 2025
Formulation and Antibacterial Evaluation of Acmella olaracea (Akarkara) Gummies Used for Toothache
Research article · 9 Apr 2025
Deep Vein Thrombosis: A Closer Look at a Silent Threat
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Pharmaceutical Care & Health Systems
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Magdy El-Salhy”

